Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Semiconductor Equipment Makers vs. Chip Designers: Who's Actually Winning the AI Cycle?

2026-08-10 20:30 • The Motley Fool Positive Axe Cap view: Selective

The article compares semiconductor equipment makers (ASML, Applied Materials) versus chip designers (Nvidia, Broadcom) in the AI boom. While equipment makers have outperformed over the past year, chip designers have higher profit margins (75-77% vs 50-54%) and greater pricing power, giving them a long-term advantage in capitalizing on the AI cycle despite massive capex investments expected to exceed $1 trillion next year.

Axe note: Chip designers show more pricing power than equipment makers despite the latter’s strong AI-driven demand.

Why AMD Stock Tumbled 18% in July

2026-08-10 20:19 • The Motley Fool Negative Axe Cap view: Selective

AMD stock fell 18% in July amid a broader semiconductor sector sell-off driven by concerns over excessive AI spending by tech companies and potential reduced returns on AI infrastructure investments. The decline was further pressured by reports that Chinese AI company DeepSeek is developing its own AI processor, intensifying competition concerns. Despite beating Q2 earnings estimates, AMD's stock continued to decline as investors recalibrated expectations given the company's premium valuation.

Axe note: AMD’s 18% drop highlights risks in chasing high-valuation tech stocks amid rising competition and AI spending fears.

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

2026-08-10 20:06 • The Motley Fool Positive Axe Cap view: Neutral

Bausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.

Axe note: Strong Canadian drug approval and earnings boost Bausch Health but South African investors should look closer at domestic pharma dynamics.

See all market stories →

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand